Released Mar 12, 2015, after the close
10-K filed Mar 12, 2015, 71 days after period end · 0001047469-15-002070
Q4 2014 · 10-K
Revenue—
Net Income-$6.23M-$6.23M N/M vs Q4 2013N/M vs Q3 2014
EPS Diluted-$0.30-$0.30 N/M vs Q4 2013N/M vs Q3 2014
Operating Incomederived-$5,943,000N/M
Operating Cash Flowderived-$6,154,000N/M
Free Cash Flowderived-$6,425,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2014 | Q4 2013 | Q4 2012 |
|---|---|---|---|
| Revenue | — | $0.00 | $643.00K |
| Net Income | -$6.23M | -$5.74M | -$4.16M |
| EPS Diluted | -$0.30 | -$0.29 | -$3.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR